In additional sensitivity analyses, reducing the hazard ratio of hypertension for ESA dosage, reducing the QALY decrement from decreased Hb, and varying the cost of ESA, QALYs were incrementally reduced at treatment targets ≥10.5 g/dl. This evidence concerns the gene GSTM1 and hypertensive disorder.